INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Pulsatile Drug Delivery Systems: A Comprehensive Review of Chronotherapeutic Paradigms

Ritu Lohar, Dr. Avinash Dhobale*

Rajgad Dnyanpeeth's College of Pharmacy, Bhor, Pune 412206, India

ARTICLE INFO

Published: 02 May 2026
Keywords:
Chronopharmaceutics, Circadian Rhythm, Lag Time, Pulsincap, Stimuli-Responsive, 3D Printing, Pharmacokinetics.
DOI:
10.5281/zenodo.19986110

ABSTRACT

The field of pharmaceutical sciences is undergoing a paradigm shift from conventional constant-release dosage forms toward "Time-Specific" and "Site-Specific" delivery, collectively known as Pulsatile Drug Delivery Systems (PDDS). These systems are engineered to release a drug rapidly and completely after a predetermined "lag time," which is essential for treating chronic diseases that exhibit circadian fluctuations. This review provides an in-depth analysis of the physiological rationale behind chronotherapy, focusing on conditions such as nocturnal asthma, rheumatoid arthritis, and cardiovascular surges where symptoms peak at specific hours of the day. We categorize PDDS into three primary technological platforms: time-controlled, stimuli-induced (pH, enzyme, and temperature-responsive), and externally regulated (magnetic and ultrasonic) systems. Furthermore, this article evaluates modern formulation strategies, including the use of rupturable coatings, swellable plugs, and osmotic pumps. Special emphasis is placed on proprietary technologies such as Pulsincap™, CODAS®, and OROS®, alongside emerging trends like 3D-printed personalized dosage forms. By synchronizing drug release with the biological clock, PDDS offer a superior alternative to sustained-release systems, significantly improving therapeutic outcomes, reducing systemic toxicity, and enhancing patient compliance.

INTRODUCTION

Traditional drug delivery focuses on maintaining constant plasma concentrations. However, many chronic ailments follow a biological clock. Chronopharmaceutics is the branch of pharmacy that addresses the metabolic and physiological changes occurring within a 24-hour cycle. PDDS is the primary tool of this discipline, ensuring that drug concentration is highest when the disease symptoms are most severe.

Pulsatile Drug Delivery Systems (PDDS) represent a chronotherapeutic approach designed to release a specific drug payload rapidly and completely after a predetermined lag time,

***Corresponding Author:** Dr. Avinash Dhobale
Address: *Rajgad Dnyanpeeth's College of Pharmacy, Bhor, Pune 412206, India*
Email : avd.lsdp@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

synchronized with the body's natural circadian rhythms. Unlike conventional sustained-release forms, PDDS address the temporal needs of diseases like nocturnal asthma, hypertension, and rheumatoid arthritis, where symptoms peak at specific hours. These systems are categorized into time-controlled (e.g., Pulsincap™), stimuli-induced (e.g., pH or enzyme-responsive), and externally regulated platforms. By aligning peak plasma concentrations with peak physiological requirements, PDDS enhance therapeutic efficacy, minimize side effects, and improve patient compliance, utilizing advanced technologies such as osmotic pumps, rupturable coatings, and emerging 3D-printed personalized dosage forms.



Fig.No:1. Comparison of Plasma Concentration Profiles

2. BIOLOGICAL RATIONALE: CIRCADIAN RHYTHMS AND DISEASE:

- The human body is governed by a circadian rhythm—a 24-hour cycle of biological activity. The effectiveness of certain drugs varies significantly based on the timing of administration.

- The biological rationale for Pulsatile Drug Delivery Systems (PDDS) is rooted in chronobiology, which demonstrates that many disease states do not maintain constant activity but rather follow the body's internal 24-hour circadian rhythm.

- These rhythms, governed by the master pacemaker in the suprachiasmatic nucleus, influence various physiological processes including blood pressure, gastric acid secretion, and airway resistance.

- Consequently, many chronic conditions exhibit predictable nocturnal or early-morning exacerbations—such as the "morning surge" in blood pressure increasing the risk of stroke, or the nighttime trough in cortisol levels triggering asthma attacks.

- By utilizing PDDS to create a programmed lag time, medication can be administered at bedtime to achieve peak plasma concentrations precisely when these clinical symptoms are at their most severe, thereby maximizing therapeutic efficacy while minimizing systemic side effects during periods of low disease activity.



Fig.No:2. Circadian Patterns of Chronic Diseases

1) **Cardiovascular Conditions:** Myocardial infarction and stroke are more frequent in the early morning (6:00 AM – 10:00 AM) due to surges in blood pressure and heart rate.

2) **Nocturnal Asthma:** Airway resistance peaks at night (2:00 AM – 4:00 AM), leading to "morning dipping."

3) **Peptic Ulcers:** Gastric acid secretion is maximal in the late evening.

4) **Arthritis:** Rheumatoid arthritis patients experience peak stiffness and pain in the morning, while Osteoarthritis pain often worsens in the evening.

3. CLASSIFICATION OF PULSATILE SYSTEMS:

3.1 Time-Controlled Systems:

- These systems utilize internal mechanisms to trigger release after a specific lag phase.

1) **Capsular Systems:** The most iconic example is the Pulsincap™. It consists of an insoluble capsule body containing the drug, sealed with a swellable hydrogel plug. Upon contact with water, the plug swells and, after a set time, is ejected, allowing the drug to release rapidly.

2) **Rupturable Systems:** The drug core is coated with an insoluble but water-permeable polymer (like Ethyl cellulose). Water enters the core, creating internal pressure (osmotic or swelling) until the coating ruptures.

Fig.No:3. Schematic of a reservoir-type pulsatile system

3) **Erodible/Soluble Coatings:** Layers of soluble polymers (like HPMC or Pectin) dissolve slowly in the GIT. Once the coating is gone, the drug pulse occurs.



Fig.No:4. Internal mechanism of the Pulsincap™ device.

3.2 Stimuli-Induced Systems:

- These systems rely on environmental triggers within the body to initiate release.

1) **pH-Dependent Systems:** Utilizing enteric polymers (Eudragit® L or S) that remain intact in the stomach (pH 1.2) but dissolve when they reach the higher pH of the small intestine (pH 6.8) or colon (pH 7.4).

2) **Enzyme-Responsive Systems:** Particularly useful for colon targeting. Polymers like Guar gum or Chitosan are degraded only by the microflora (enzymes) present in the large intestine.

3) **Temperature-Responsive Systems:** Hydrogels that undergo a phase transition at a specific temperature, releasing the drug only when the body temperature reaches a certain threshold (useful for fever-related triggers).

3.3 Externally Regulated Systems:

- These are active systems controlled from outside the body.

1) **Magnetically Triggered:** Incorporating magnetic particles into a polymer matrix. Application of an external magnetic field causes the drug to "squeeze" out.

2) **Electro-Responsive:** Utilizing conductive polymers that change porosity when an electrical pulse is applied.

4. DESIGN AND FORMULATION STRATEGIES:

- Designing a PDDS requires careful selection of:

1. **Excipients:** Swelling agents (Cross-povidone), Osmogens (NaCl), and specialized polymers.

2. **Lag Time Determinants:** Coating thickness, polymer viscosity, and orifice size in osmotic systems.

3. **Dosage Form:** Multiparticulate systems (pellets/beads) are often preferred over single-unit systems (tablets) as they provide more consistent gastric emptying and lower risk of dose dumping.

4. **Standardization of Manufacturing Parameters:** Critical process parameters (CPPs) such as spray rate during coating and the compression force of the core must be standardized, as even slight variations can cause significant shifts in the lag time.

5. **Use of Bioadhesive Polymers:** To prevent the dosage form from being excreted before the "pulse" occurs (especially for colon targeting), adding bioadhesive agents (like Carbopol) helps the system remain at the target absorption site during the lag phase.

5. MARKETED TECHNOLOGIES AND PROPRIETARY PLATFORMS:

Sr. No.	Technology	Mechanism	Clinical Application
1)	**CODAS®**	Multi-particulate beads with pH-independent coating	Verapamil (Verelan® PM) for Hypertension
2)	**DIFFUCAPS®**	Layers of specialized coatings for tailored lag	Propranolol (Innopran® XL) for Angina
3)	**OROS®**	Osmotic "Push-Pull" system with a laser orifice	Covera-HS® for Cardiovascular protection
4)	**TIMERx®**	Xanthan-Locust bean gum hydrogel matrix	Various Chronotherapeutic needs
5)	**PULSYS™**	Multiple pulses from a single tablet	Amoxicillin (Moxatag™) for Bacterial infections



Fig.No:5. Cross-section of the OROS® (Osmotic Release Oral System)

6. RECENT ADVANCEMENTS: 3D PRINTING AND BEYOND:

The pharmaceutical industry is transitioning toward 3D Printing (3DP) for PDDS. 3DP allows for the creation of "complex internal architectures" (e.g., hollow shells or multi-chambered tablets) that are impossible with traditional compression. This enables extremely precise, personalized lag times for individual patients.

7. CONCLUSION

Pulsatile Drug Delivery Systems are a vital component of modern medicine, moving beyond the "one-size-fits-all" approach to a "time-is-of-the-essence" paradigm. While challenges remain regarding manufacturing complexity and biological variability, the integration of new materials and 3D printing ensures that PDDS will remain at the forefront of pharmaceutical innovation.

REFERENCES

1. Kumar PSSP, Srinivas L. A review on pulsatile drug delivery systems. IJPSR 2023; 14(7): 3246-54.
2. Singh A, Tahilani P. Pulsatile Drug Delivery Systems for the Treatment of Asthma. IJPSI 2025; 14(3): 135-139.
3. Valte YB, et al. Review on Pulsatile Drug Delivery System. IJPRS 2015; 4(1-2).
4. Pathak D. Novel Concept of Drug Delivery Based on Chronotherapy: A Review. IJPRT 2014; 4(2): 23-27.
5. Ubaidulla U, Vimal raj E. A Comprehensive Review on Novel Drug Delivery Systems. IJRPP 2024; 13(4): 417-419.
6. Shidhaye SS, et al. Pulsatile Delivery Systems: An Approach for Chronotherapeutic Diseases. Sys Rev Pharm 2010; 1(1): 55-61.
7. Vaniprasanna T, et al. Chronotherapeutic Drug Delivery Systems Based on Floating Concept. JAMPS 2016; 7(3): 1-18.
8. Dash SK, et al. Pulsatile Drug Delivery System (PDDS) for Optimum Therapy. JPRI 2022; 34(31B): 28-45.
9. Shelke AP, et al. Pulsatile drug delivery system: A review. WJBPHS 2025; 21(02): 457-466.
10. Maroni A, et al. Oral pulsatile delivery: Rationale and formulations. Int J Pharm 2010; 398: 1-8.
11. Smolensky MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev 2007; 59: 828-51.
12. Patel V, Patel V. Pulsatile drug delivery systems-A Review. IJPSR 2015; 6(9): 3676-3688.
13. Bussemer T, et al. Pulsatile drug-delivery systems. Crit Rev Ther Drug Carrier Syst 2001; 18(5): 433-58.
14. Kikuchi A, Okano T. Pulsatile drug release control using hydrogels. Adv Drug Deliv Rev 2002; 54: 53-77.
15. Youan BC. Chronopharmaceutics: gimmick or clinically relevant? J Control Release 2004; 98: 337-53.
16. Gazzaniga A, et al. Chronopharmaceutics: Oral pulsatile drug delivery systems. Expert Opin Drug Deliv 2008; 5(7): 775-86.
17. Roy P, Shahiwala A. Multiparticulate formulation approach to pulsatile drug delivery. J Control Release 2009; 134: 74-80.
18. Jain D, et al. Recent technologies in pulsatile drug delivery systems. Biomatter 2011; 1(1): 57-65.
19. Stevens HN, et al. The tolerability of Pulsincap™ capsules. J Control Release 2002; 79: 167-78.
20. Lemmer B. The clinical relevance of chronopharmacology. Arzneimittelforschung 2006; 56(6a): 426-35.
21. Ravichandran V, et al. Pulsatile Drug Delivery System. Biomed Pharmacol J 2009; 2(2): 749.
22. Gouse Firoz S, et al. Novel approaches for pulsatile drug delivery systems. J Crit Rev 2020; 7(13): 2282.
23. Sharma GS, et al. Recent trends in pulsatile drug delivery systems: A Review. Int J Drug Deliv 2012; 2: 200.
24. Rasve G, et al. Pulsatile drug delivery system current scenario. Int J Pharm Biosci 2011; 2(3).

25. Kamalpuria N, et al. The latest methods and technologies of PDDS. IJPLS 2017; 8: 46-58.
26. Pranga G, et al. Pulsatile Drug Delivery System-An Overview. IJPDT 2013; 3(2): 97.
27. Sagat DS, et al. Pulsatile Drug Delivery System-A Review. IJPPR 2019; 16(2): 488.
28. Amol V, et al. Review on Pulsatile Drug Delivery System. IJCAP 2013; 4: 77-84.
29. Devi R, Kumar S. Pulsatile drug delivery system: new paradigms. IJIPSR 2017; 5: 34-49.
30. Kaur J, et al. Pulsatile Drug Delivery System: A Comprehensive Review. J Pharm Res 2016; 10: 12-25.
31. Vats A, Singh JK. Chronotherapeutics: An Optimistic Approach to Drug Delivery. International Journal of Research in Pharmaceutical Sciences. 2020; 11(3): 4478-4485.
32. Gajendran B, et al. Pulsatile Drug Delivery System: A Review on Recent Trends and Technologies. Journal of Drug Delivery and Therapeutics. 2022; 13(6): 124-130.
33. Reddy GG, et al. Design and Evaluation of Albuterol Sulphate and Theophylline Pulsincap Drug Delivery System for Chronotherapy of Asthma. Journal of Drug Delivery and Therapeutics. 2024; 14(2): 134-141.
34. Gao J, et al. The Future of Drug Delivery: 3D Printing and Beyond. Chemistry of Materials. 2023; 35(2): 359-363.
35. Kaur J, et al. Formulation and Evaluation of Pulsatile Drug Delivery System of Anti-Asthmatic Drug. International Journal of Pharmacy & Pharmaceutical Research.
36. Pani L, Marchese G. Expected Clinical Benefits of Extended-Release Formulations in Circadian Disorders. Expert Opinion on Drug Delivery. 2009; 6(3): 319-331.2023; 27(4): 238-270.

HOW TO CITE: Ritu Lohar, Dr. Avinash Dhobale, Pulsatile Drug Delivery Systems: A Comprehensive Review of Chronotherapeutic Paradigms, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 5, 286-292. https://doi.org/10.5281/zenodo.19986110